Zobrazeno 1 - 10
of 126
pro vyhledávání: '"E. Svedmyr"'
Autor:
Ulla Axdorph, Håkan Mellstedt, Göran Holm, Magnus Björkholm, E. Svedmyr, Ola Landgren, G. Grimfors, K. Merk, B. Johansson
Publikováno v:
Annals of Oncology. 6:895-899
Background : The optimal number of chemotherapy courses in responding patients with advanced-stage Hodgkin's disease (HD) is unknown. Patients and methods : With minimizing chemotherapy and thereby reducing late complications as the objective, patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5cd781f388e8db4eb428ea4191d4a67
https://doi.org/10.1093/oxfordjournals.annonc.a059356
https://doi.org/10.1093/oxfordjournals.annonc.a059356
Autor:
R. Lerner, A. Killander, Håkan Mellstedt, Åke Öst, A.-M. Stalfelt, B. Simonsson, B. Wadman, Eva Kimby, E. Svedmyr, K.-H. Robért, B. Johansson, Magnus Björkholm, Eva Löfvenberg, Bengt Glimelius, Anders Wahlin, Christer Sundström, Gunnar Juliusson, Hans Hagberg, M. Järnmark, Gösta Gahrton, A.-M. Udén, C. Lindemalm, H. Johansson, U. Pettersson
Publikováno v:
Annals of Oncology. 5:S67-S71
Two hundred fifty-nine previously untreated patients with low-grade non-Hodgkin's lymphomas (NHLs), Ann Arbor stages III and IV, entered a randomized multicenter trial comparing the therapeutic effect of chlorambucil/prednisone (ChP) vs. CHOP. All pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8901c02cbee4ea338ba7ec7e19215a8d
https://doi.org/10.1093/annonc/5.suppl_2.s67
https://doi.org/10.1093/annonc/5.suppl_2.s67
BACKGROUND. Cytologic distinction between follicle center lymphoma (FCL) and mantle cell lymphoma (MCL) is difficult with cytomorphology alone and requires immunophenotyping. The current study describes the distinction between follicle center and man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::3e7ef489fc6294e7667d1309475948b6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3052123
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3052123
Autor:
Magnus Björkholm, A. Hedlund, P. Bernell, G. Grimfors, K. Merk, S. Widell, E. Ösby, Jan Liliemark, Fredrik Celsing, E. Svedmyr
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 9(11)
Summary Background Second- and third-generation chemotherapy protocols for the treatment of aggressive non-Hodgkin’s lymphomas (NHL) have considerable, and age-related, toxic effects. In addition, they do not seem to prolong overall survival in com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13c2555902c18838de9292e654d16e10
https://pubmed.ncbi.nlm.nih.gov/9862052
https://pubmed.ncbi.nlm.nih.gov/9862052
Autor:
M, Björkholm, U, Axdorph, G, Grimfors, K, Merk, B, Johansson, O, Landgren, E, Svedmyr, H, Mellstedt, G, Holm
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 6(9)
The optimal number of chemotherapy courses in responding patients with advanced-stage Hodgkin's disease (HD) is unknown.With minimizing chemotherapy and thereby reducing late complications as the objective, patients with advanced HD were randomized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b02b0cb01162dd02c861f9d8d5521320
https://pubmed.ncbi.nlm.nih.gov/8624292
https://pubmed.ncbi.nlm.nih.gov/8624292
Publikováno v:
Lakartidningen. 88(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f6461dbc1a9be0ec150ab204e5b8f9ce
https://pubmed.ncbi.nlm.nih.gov/1999990
https://pubmed.ncbi.nlm.nih.gov/1999990
Autor:
Robert Hast, A.-M. Stalfelt, B. Johansson, Christer Paul, A. Killander, Gunnar Juliusson, M. Björeman, Håkan Mellstedt, G. Gahrton, G. Brenning, B. Simonsson, E. Svedmyr, B. Smedmyr, Eva Ösby, Magnus Björkholm, M. Järnmark, A.-M. Udén, A. Åhre, Bo Nilsson, B. Wadman, Anders Österborg, Eva Kimby, Gunnar Grimfors, R. Lerner, H. Gyllenhammar
Publikováno v:
Acta oncologica (Stockholm, Sweden). 29(6)
Eighty-one previously untreated patients with multiple myeloma stage II entered a randomized trial comparing oral melphalan (0.25 mg/kg/day; n = 40) with intravenous melphalan (0.125 mg/kg/day; n = 41) in combination with oral prednisone (2 mg/kg/day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8309d3b6d3d368815820841eab9d7d99
https://pubmed.ncbi.nlm.nih.gov/2223143
https://pubmed.ncbi.nlm.nih.gov/2223143
Publikováno v:
The Journal of Immunology. 127:293-300
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bfb687b00b3c0f8ca1da21c0026691b
https://doi.org/10.4049/jimmunol.127.1.293
https://doi.org/10.4049/jimmunol.127.1.293
Publikováno v:
Israel journal of medical sciences. 13(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8f30525a380768151ce949f9456cae3f
https://pubmed.ncbi.nlm.nih.gov/303641
https://pubmed.ncbi.nlm.nih.gov/303641
Publikováno v:
Journal of clinicallaboratory immunology. 1(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e05030635c23511c1765d75f1e745014
https://pubmed.ncbi.nlm.nih.gov/228038
https://pubmed.ncbi.nlm.nih.gov/228038